Immunotherapy showdown: new drug challenges chemo for lung cancer

NCT ID NCT03003962

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

Summary

This study compared a new immunotherapy drug called durvalumab against standard chemotherapy as the first treatment for advanced non-small cell lung cancer. It involved 669 patients whose cancer had a specific biomarker (high PD-L1 expression) and had not received prior treatment. The main goal was to see if the immunotherapy helped patients live longer than chemotherapy.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Research Site

Anaheim, California, 92801, United States
Research Site

Box Hill, 3128, Australia
Research Site

Gosford, 2250, Australia
Research Site

Kogarah, 2217, Australia
Research Site

St Leonards, 2065, Australia
Research Site

Beijing, 100032, China
Research Site

Beijing, 100142, China
Research Site

Beijing, 100853, China
Research Site

Bengbu, 233004, China
Research Site

Changchun, 130000, China
Research Site

Changsha, 410013, China
Research Site

Chengdu, 610041, China
Research Site

Chongqing, 400030, China
Research Site

Guangzhou, 510080, China
Research Site

Guangzhou, 510095, China
Research Site

Haikou, 570311, China
Research Site

Hangzhou, 310003, China
Research Site

Hangzhou, 310006, China
Research Site

Hangzhou, 310009, China
Research Site

Hangzhou, 310022, China
Research Site

Jinan, 250031, China
Research Site

Linhai, 317000, China
Research Site

Nanchang, 330006, China
Research Site

Nanjing, 210009, China
Research Site

Ningbo, 315010, China
Research Site

Shanghai, 200030, China
Research Site

Shenyang, 110042, China
Research Site

Shijiazhuang, 050020, China
Research Site

Ürümqi, 830000, China
Research Site

Ürümqi, 830054, China
Research Site

Wanzhou, 404000, China
Research Site

Wenzhou, CN-325000, China
Research Site

Wuhan, 430010, China
Research Site

Wuhan, 430022, China
Research Site

Wuhan, 430030, China
Research Site

Xi'an, 710038, China
Research Site

Xi'an, 710061, China
Research Site

Zhengzhou, 450008, China
Research Site

Zhuhai, 519099, China
Research Site

Budapest, 1083, Hungary
Research Site

Budapest, 1121, Hungary
Research Site

Budapest, 1122, Hungary
Research Site

Deszk, 6772, Hungary
Research Site

Farkasgyepü, 8582, Hungary
Research Site

Gyöngyös - Mátraháza, 3200, Hungary
Research Site

Székesfehérvár, 8000, Hungary
Research Site

Törökbálint, 2045, Hungary
Research Site

Almelo, 7600SZ, Netherlands
Research Site

Bialystok, 15-027, Poland
Research Site

Grudziądz, 86-300, Poland
Research Site

Koszalin, 75-581, Poland
Research Site

Lublin, 20-090, Poland
Research Site

Mrozy, 05-320, Poland
Research Site

Warsaw, 02-781, Poland
Research Site

Wroclaw, 53-413, Poland
Research Site

Arkhangelsk, 163045, Russia
Research Site

Moscow, 115478, Russia
Research Site

Novosibirsk, 630108, Russia
Research Site

Omsk, 644013, Russia
Research Site

Rostov-on-Don, 344037, Russia
Research Site

Saint Petersburg, 194291, Russia
Research Site

Saint Petersburg, 196603, Russia
Research Site

Saint Petersburg, 197183, Russia
Research Site

Saint Petersburg, 197342, Russia
Research Site

Saint Petersburg, 197758, Russia
Research Site

Volgograd, 400138, Russia
Research Site

Changwon-si, 51353, South Korea
Research Site

Cheongju-si, 28644, South Korea
Research Site

Daegu, 42415, South Korea
Research Site

Incheon, 21565, South Korea
Research Site

Jinju, 660-702, South Korea
Research Site

Seoul, 03722, South Korea
Research Site

Suwon, 16499, South Korea
Research Site

Taichung, 402, Taiwan
Research Site

Taichung, 40705, Taiwan
Research Site

Taipei, 112, Taiwan
Research Site

Taipei, 235, Taiwan
Research Site

Bangkok, 10330, Thailand
Research Site

Bangkok, 10700, Thailand
Research Site

Muang, 50200, Thailand
Research Site

Songkhla, 90110, Thailand
Research Site

Ankara, 06490, Turkey (Türkiye)
Research Site

Istanbul, 34030, Turkey (Türkiye)
Research Site

Istanbul, 34854, Turkey (Türkiye)
Research Site

Malatya, 44100, Turkey (Türkiye)
Research Site

Pamukkale, 20070, Turkey (Türkiye)
Research Site

Can Tho, 900000, Vietnam
Research Site

Hanoi, 100000, Vietnam
Research Site

Hanoi, 10000, Vietnam
Research Site

Ho Chi Minh City, 10000, Vietnam
Research Site

Ho Chi Minh City, 700000, Vietnam
Research Site

Ho Chi Minh City, 70000, Vietnam

Conditions

Explore the condition pages connected to this study.

NON SMALL CELL LUNG CARCINOMA NSCLC